Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 18, 2025; 15(2): 101517
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.101517
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.101517
C3 glomerulopathy post kidney transplantation: A single center experience
Jonathan Zuckerman, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States
Phuong-Thu Pham, Meena Parakkal, Mrinalini Sarkar, Suphamai Bunnapradist, Erik L Lum, Department of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States
Alexis F Velazquez, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States
Michael A Pablos, Division of Nephrology, Harbor Medical Center, University of California, Los Angeles, CA 90095, United States
Author contributions: Lum EL, Zuckerman J, and Bunnapradist S generated conceptualization; Lum EL, Parakkal M, Zuckerman J, and Velazquez AF performed data collection; Lum EL, Pham PT, Zuckerman J, Pablos MA, Velazquez AF, Bunnapradist S, Sarkar M, and Parakkal M wrote the manuscript and prepared tables and figures.
Institutional review board statement: This study was approved by the University of California Los Angeles institutional review board (No. 12-000991).
Informed consent statement: Patients were not required to provide informed consent for this study because the data was obtained using anonymous electronic medical records after patient had agreed to treatment with written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Erik L Lum, MD, Associate Professor, Department of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, 200 Medical Center, Suite 565, Los Angeles, CA 90095, United States. elum@mednet.ucla.edu
Received: September 17, 2024
Revised: November 8, 2024
Accepted: December 25, 2024
Published online: June 18, 2025
Processing time: 156 Days and 21.3 Hours
Revised: November 8, 2024
Accepted: December 25, 2024
Published online: June 18, 2025
Processing time: 156 Days and 21.3 Hours
Core Tip
Core Tip: C3 glomerulopathy is a highly recurrent disease in kidney transplant recipients, resulting in premature allograft loss. In this single center retrospective observational study recipients with underling C3 glomerulopathy experienced early recurrence with a median time of 7 months post kidney transplantation. The most common finding on kidney biopsy was endocapillary proliferative glomerulonephritis. Treatment with eculizumab was associated with a median graft survival of 73 months, compared to a median graft survival of 22 months in untreated patient with recurrent C3 glomerulopathy.